A new HIV Medicine study identified several barriers to routine HIV testing in emergency departments and acute medical units in the UK and US.
People with both HIV and risk factors for heart disease and stroke were less likely to be treated with cholesterol-lowering statin drugs and aspirin than patients without HIV.
New data published today in Immunity further illuminate how some human beings generate powerful, HIV-blocking antibodies. Led by scientists at the International AIDS Vaccine Initiative (IAVI) and The Scripps Research Institute (TSRI), the results offer important insight into a potential AIDS vaccine design.
Infection researchers from the German Primate Center (DPZ) -- Leibniz Institute for Primate Research have in cooperation with international colleagues tested a new vaccination strategy against the HIV-related simian immunodeficiency virus (SIV) in rhesus monkeys. For this, the researchers used a vaccine that consisted of two components.
New approaches are needed to control the spread of epidemic diseases, according to the developers of a new model of the way pathogens can 'cooperate'. Their study examined the ways two pathogens work together, finding that cooperativity between contagion processes is likely to make the spread of contagious infections more severe.
A new study that compared HIV-positive women over 50 years of age with their younger HIV-infected cohorts found that while the older women were less likely to be sexually active and to report condomless sex with a male partner, those who were sexually active were not as likely to undergo screening for gonorrhea, chlamydia, or syphilis than their younger counterparts.
New research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease, a potentially lethal complication of bone marrow stem cell transplantation. CytoDyn is currently enrolling patients in a Phase 2 clinical trial with PRO 140 for the prevention of GvHD in leukemia patients undergoing BMSC transplantation.
Sexual transmission is the main method of human immunodeficiency virus type 1 (HIV-1) infection in women. The effectiveness of topical microbicides for HIV-1 prevention can be inconsistent and insufficient, which are associated with low adherence rates and/or product misuse. To address these difficulties, researchers presenting at the 2017 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition designed extended release vaginal films which could be effective in HIV prevention for up to seven days.
Scientists have discovered a peculiarity in the genetic code of HIV that might explain how this and other viruses evolved ways to dodge our immune system. The findings could make it possible to develop safer vaccines.
Adults with human immunodeficiency virus (HIV) and good viral suppression on combination antiretroviral therapy had poorer cognition and reduced brain thickness and volume on magnetic resonance imaging than adults without HIV, but changes over time in cognitive performance and brain structure were similar between the two groups over two years.